Cellectis S.A. American Depositary Shares
CLLS Real Time Price USDRecent trades of CLLS by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in CLLS holdings by institutional investors
Quarterly net insider trading by CLLS's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
CLLS Estimated quarterly lobbying spending
CLLS Revenue by Segment or Geography
New CLLS patent grants
-
Patent Title: Targeted gene insertion for improved immune cells therapy Aug. 19, 2025
-
Patent Title: Method for improving production of car t cells Jul. 22, 2025
-
Patent Title: Method for generating t-cells compatible for allogenic transplantation Mar. 18, 2025
-
Patent Title: Targeted gene integration of crs inhibitor genes for improved immune cells therapy Feb. 11, 2025
-
Patent Title: Targeted gene integration of nk inhibitors genes for improved immune cells therapy Jan. 28, 2025
-
Patent Title: Cellular immunotherapy for repetitive administration Nov. 19, 2024
-
Patent Title: Universal anti-cd22 chimeric antigen receptor engineered immune cells Nov. 05, 2024
-
Patent Title: Engineering wheat with increased dietary fiber Jun. 18, 2024
-
Patent Title: Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system Apr. 16, 2024
-
Patent Title: Universal anti-cd22 chimeric antigen receptor engineered immune cells Apr. 02, 2024
-
Patent Title: Cd123 specific chimeric antigen receptors for cancer immunotherapy Mar. 05, 2024
-
Patent Title: Engineered immune cells resistant to tumor microenvironment Feb. 20, 2024
-
Patent Title: Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy Feb. 06, 2024
-
Patent Title: Targeted gene insertion for improved immune cells therapy Jan. 16, 2024
-
Patent Title: Method for generating t-cells compatible for allogenic transplantation Nov. 21, 2023
-
Patent Title: Sequence specific reagents targeting ccr5 in primary hematopoietic cells Sep. 26, 2023
-
Patent Title: Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells Jul. 04, 2023
-
Patent Title: Universal chimeric antigen receptor t cells specific for cd22 Jul. 04, 2023
-
Patent Title: Compact scaffold of cas9 in the type ii crispr system Jun. 27, 2023
-
Patent Title: Sequential gene editing in primary immune cells Jun. 13, 2023
-
Patent Title: Canola with high oleic acid Apr. 11, 2023
-
Patent Title: Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy Mar. 14, 2023
-
Patent Title: Mutant Feb. 14, 2023
-
Patent Title: Method for making nicotiana plants with mutations in xylt and fuct alleles using rare-cutting endonucleases Jan. 17, 2023
-
Patent Title: Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy Nov. 15, 2022
-
Patent Title: Alfalfa with reduced lignin composition Oct. 25, 2022
-
Patent Title: Sequential gene editing in primary immune cells Oct. 11, 2022
-
Patent Title: Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells Aug. 16, 2022
-
Patent Title: Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system Jun. 21, 2022
-
Patent Title: Cd123 specific chimeric antigen receptors for cancer immunotherapy Apr. 17, 2018
-
Patent Title: Cd33 specific chimeric antigen receptors for cancer immunotherapy Apr. 17, 2018
-
Patent Title: Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system Feb. 13, 2018
-
Patent Title: Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system Jan. 02, 2018
-
Patent Title: Method for increasing the efficiency of double-strand-break induced mutagenesis Jan. 10, 2017
-
Patent Title: Meganuclease recombination system Jun. 14, 2016
-
Patent Title: Use of endonucleases for inserting transgenes into safe harbor loci Mar. 22, 2016
-
Patent Title: Meganuclease variants cleaving a dna target sequence from a glutamine synthetase gene and uses thereof Mar. 01, 2016
-
Patent Title: Method for modulating the efficiency of double-strand break-induced mutagenesis Jun. 02, 2015
-
Patent Title: Method and apparatus for the delivery of polynucleotide vaccines to mammalian skin Mar. 17, 2015
-
Patent Title: Method for modulating double-strand break-induced homologous recombination Dec. 09, 2014
-
Patent Title: Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations Aug. 12, 2014
-
Patent Title: Population of multipotent cardiac precursor cells derived from human blastocysts derived stem cells Aug. 12, 2014
-
Patent Title: I- May. 06, 2014
-
Patent Title: Meganuclease recombination system Jul. 02, 2013
-
Patent Title: Meganuclease variants cleaving a dna target sequence from the mouse rosa26 locus and uses thereof Apr. 23, 2013
-
Patent Title: Anti-bacterial composition especially for controlling gram-negative bacteria, comprising a peptide and an advantageously hydrophobic anti-bacterial agent Oct. 23, 2012
-
Patent Title: I- Jul. 03, 2012
-
Patent Title: Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei Aug. 23, 2011
-
Patent Title: I- Mar. 01, 2011
-
Patent Title: Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof Nov. 30, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded to CLLS from public contracts
Recent insights relating to CLLS
Recent picks made for CLLS stock on CNBC
ETFs with the largest estimated holdings in CLLS
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $CLLS stock a Buy, Sell, or Hold?
- What is the price target for $CLLS stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $CLLS stock?
- Who owns the most shares of $CLLS stock?
- What funds own $CLLS stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CLLS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.